tbc-11251 has been researched along with Heart Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barst, RJ; DeMarco, T; Frost, AE; Hill, N; Horn, E; Langleben, D; McLaughlin, V; Oudiz, R; Robbins, IM; Rubenfire, M; Schilz, R; Shapiro, S; Tapson, VF; Zwicke, D | 1 |
1 trial(s) available for tbc-11251 and Heart Diseases
| Article | Year |
|---|---|
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect.
Topics: Double-Blind Method; Endothelin Receptor Antagonists; Endpoint Determination; Exercise Test; Heart Diseases; Humans; Hypertension, Pulmonary; Isoxazoles; Research Design; Thiophenes; Walking | 2005 |